IDYA News

Biocytogen kondigt klinische mijlpaal aan met eerste patiënt die wordt behandeld in fase 1-onderzoek naar IDEAYA's eerste in zijn klasse B7H3/PTK7 bispecifieke TOP1 ADC IDE034

Biocytogen annuncia un importante traguardo clinico – trattato il primo paziente nel trial di fase 1 di IDE034, l’ADC TOP1 bispecifico per B7H3/PTK7 “first-in-class” sviluppato da IDEAYA

Biocytogen verkündet klinischen Meilenstein: Erster Patient in Phase-1-Studie von IDEAYAs erstklassigem B7H3/PTK7-bispezifischen TOP1-ADC IDE034 behandelt

Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034

Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034

百奥赛图宣布达成重要临床里程碑，合作伙伴IDEAYA启动双抗ADC IDE034 I期临床并完成首例患者给药

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC

IDEAYA Biosciences Announces Appointment of Dr. Theodora (Theo) Ross, M.D., Ph.D., as Chief Development Officer

MATTERWORKS, INC. ANNOUNCES UPDATE TO LEADERSHIP TEAM